CoChat
Sign Up
Cited by 85Ubiquitin and proteasome pathwaysProtease and Inhibitor MechanismsProtein Degradation and Inhibitors

Clinical development of novel proteasome inhibitors for cancer treatment

Open access
Yang, Huanjie, Zonder, Jeffrey A, Dou, Q Ping·2009·Expert Opinion on Investigational Drugs
DOI 10.1517/13543780903002074PMC PMC3758888
Open this paper in CoChat — free account

Abstract

BACKGROUND: Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy. OBJECTIVE: This review summarizes recent results from cancer clinical trials using specific proteasome inhibitors or some natural compounds that have proteasome-inhibitory effects. METHODS: A literature search was carried out using PubMed. Results about the clinical application of specific proteasome inhibitors and natural products with proteasome-inhibitory activity for cancer prevention or therapy were reviewed. RESULTS/CONCLUSION: Bortezomib, the reversible proteasome inhibitor that first entered clinical trials, has been studied extensively as a single agent and in combination with glucocorticoids, cytotoxic agents, immunomodulatory drugs and radiation as treatment for multiple myeloma and other hematological malignancies. The results in some cases have been impressive. There is less evidence of bortezomib's efficacy in solid tumors. Novel irreversible proteasome inhibitors, NPI-0052 and carfilzomib, have also been developed and clinical trials are underway. Natural products with proteasome-inhibitory effects, such as green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), soy isoflavone genistein, and the spice turmeric compound curcumin, have been studied alone and in combination with traditional chemotherapy and radiotherapy against various cancers. There is also interest in developing these natural compounds as potential chemopreventive agents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543780903002074

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 127

  1. [1]Glotzer M Murray AW Kirschner MW Cyclin is degraded by the ubiquitin pathway. Nature 1991 349 132 8 1846030
  2. [2]Won KA Reed SI Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 1996 15 4182 93 8861947 PMC452142
  3. [4]Chen W Lee J Cho SY Fine HA Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 2004 64 3949 57 15173007
  4. [5]Scheffner M Werness BA Huibregtse JM The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990 63 1129 36 2175676
  5. [6]Li B Dou QP Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000 97 3850 5 10725400 PMC18105
  6. [7]Pagano M Tam SW Theodoras AM Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995 269 682 5 7624798
  7. [8]Chen Z Hagler J Palombella VJ Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995 9 1586 97 7628694
  8. [9]Alkalay I Yaron A Hatzubai A Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995 92 10599 603 7479848 PMC40659
  9. [10]Adams J The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004 5 417 21 15144949
  10. [11]Dou QP Goldfarb RH Bortezomib (Millennium Pharmaceuticals). IDrugs 2002 5 828 34 12802699
  11. [12]Kraus M Ruckrich T Reich M Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007 21 84 92 17024115
  12. [13]Jakob C Egerer K Liebisch P Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007 109 2100 5 17095627
  13. [14]Adams J Palombella VJ Sausville EA Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999 59 2615 22 10363983
  14. [15]Sterz J von Metzler I Hahne JC The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008 17 879 95 18491989
  15. [16]Orlowski RZ Stinchcombe TE Mitchell BS Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002 20 4420 7 12431963
  16. [17]Jagannath S Barlogie B Berenson J A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004 127 165 72 15461622
  17. [18]Jagannath S Barlogie B Berenson JR Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008 143 537 40 18783399
  18. [19]Richardson PG Barlogie B Berenson J A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 348 2609 17 12826635
  19. Richardson PG Sonneveld P Schuster MW Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 352 2487 98 Bortezomib efficacy was shown superior to high-dose dexamethasone for the treatment of relapsed MM in a large Phase III study. 15958804
  20. [21]Richardson PG Sonneveld P Schuster M Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007 110 3557 60 17690257
  21. [22]Chanan-Khan A Sonneveld P Schuster MW Analysis of herpes zoster events among bortezomib-treated patients in the Phase III APEX study. J Clin Oncol 2008 26 4784 90 18711175
  22. San Miguel JF Schlag R Khuageva NK Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 359 906 17 Effective strategy using bortezomib combination as initial treatment for MM. 18753647
  23. [24]Orlowski RZ Nagler A Sonneveld P Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 25 3892 901 17679727
  24. [25]Blade J Sonneveld P San Miguel JF Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008 8 352 5 19064400
  25. [26]Oakervee HE Popat R Curry N PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005 129 755 62 15953001
  26. [28]Ciolli S Leoni F Gigli F Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 2006 47 171 3 16321846
  27. Reece DE Rodriguez GP Chen C Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008 26 4777 83 Highly effective bortezomib combination strategy as treatment for relapsed MM. 18645194
  28. [32]Barlogie B Anaissie E van Rhee F Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007 138 176 85 17593024
  29. [33]Goel A Dispenzieri A Greipp PR PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005 33 784 95 15963854
  30. [34]Mohiuddin MM Harmon DC Delaney TF Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report. J Chemother 2005 17 343 6 16038531
  31. [35]Berges O Decaudin D Servois V Kirova YM Concurrent radiation therapy and bortezomib in myeloma patient. Radiother Oncol 2008 86 290 2 18199515
  32. [36]Terpos E Dimopoulos MA Sezer O The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007 21 1875 84 17611556
  33. [37]Heider U Kaiser M Muller C Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006 77 233 8 16923110
  34. [38]von Metzler I Krebbel H Hecht M Bortezomib inhibits human osteoclastogenesis. Leukemia 2007 21 2025 34 17581612
  35. [39]Anderson KC Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 2007 35 155 62 17379101
  36. [40]Hideshima T Catley L Raje N Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007 138 783 91 17760810
  37. [41]Goy A Younes A McLaughlin P Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005 23 667 75 15613697
  38. [42]O'Connor OA Wright J Moskowitz C Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005 23 676 84 15613699
  39. [43]Fisher RI Bernstein SH Kahl BS Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006 24 4867 74 17001068
  40. [44]Belch A Kouroukis CT Crump M A Phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007 18 116 21 16971665
  41. [45]Younes A Pro B Fayad L Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006 107 1731 2 16461762
  42. [46]Mendler JH Kelly J Voci S Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008 19 1759 64 18504251 PMC2735068
  43. [47]Yang CH Gonzalez-Angulo AM Reuben JM Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006 17 813 7 16403809
  44. [48]Engel RH Brown JA Von Roenn JH A Phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007 25 733 7 17952740
  45. [49]Cresta S Sessa C Catapano CV Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008 44 1829 34 18640031
  46. [50]Schmid P Kuhnhardt D Kiewe P A Phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008 19 871 6 18209010
  47. [51]Awada A Albanell J Canney PA Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a Phase I/II dose-escalation study. Br J Cancer 2008 98 1500 7 18454159 PMC2391111
  48. [52]Jones SE Erban J Overmoyer B Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005 23 5542 51 16110015
  49. [53]Papandreou CN Daliani DD Nix D Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004 22 2108 21 15169797
  50. [54]Dreicer R Petrylak D Agus D Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007 13 1208 15 17317831
  51. [55]Hainsworth JD Meluch AA Spigel DR Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network Phase II trial. Clin Genitourin Cancer 2007 5 278 83 17553208
  52. [56]Morris MJ Kelly WK Slovin S A Phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 2007 178 2378 83 17936848
  53. [57]Davies AM Ho C Metzger AS Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2007 2 1112 6 18090584
  54. [58]Alberts SR Foster NR Morton RF PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized Phase II study. Ann Oncol 2005 16 1654 61 16085692
  55. [59]Ryan DP O'Neil BH Supko JG A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006 107 2688 97 17075878
  56. [60]Aghajanian C Dizon DS Sabbatini P Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005 23 5943 9 16135465
  57. [61]Ramirez PT Landen CN Jr Coleman RL Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol 2008 108 68 71 17905421
  58. [62]Shah MH Young D Kindler HL Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004 10 6111 8 15447997
  59. [63]Van Waes C Chang AA Lebowitz PF Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005 63 1400 12 16005577
  60. [64]Sloss CM Wang F Liu R Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008 14 5116 23 18698029 PMC2774251
  61. [65]Ayala G Yan J Li R Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res 2008 14 7511 8 19010869 PMC2820291
  62. [66]Feling RH Buchanan GO Mincer TJ Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003 42 355 7 12548698
  63. [67]Fenteany G Standaert RF Lane WS Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995 268 726 31 7732382
  64. [68]Groll M Huber R Potts BC Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006 128 5136 41 16608349
  65. [69]Chauhan D Catley L Li G A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005 8 407 19 16286248
  66. [72]Chauhan D Singh AV Brahmandam M Combination of a novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vivo synergistic cytotoxicity in multiple myeloma [abstract 3662]. Blood 2008 112 Suppl 1 PMC2815518 19965674
  67. [73]Kuhn DJ Chen Q Voorhees PM Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007 110 3281 90 17591945 PMC2200918
  68. [76]Nam S Smith DM Dou QP Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001 276 13322 30 11278274
  69. [77]Landis-Piwowar KR Huo C Chen D A novel prodrug of the green tea polyphenol (−)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007 67 4303 10 17483343
  70. Bettuzzi S Brausi M Rizzi F Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006 66 1234 40 Chemopreventive effect of green tea was demonstrated on prostate cancer development. 16424063
  71. [79]Jian L Xie LP Lee AH Binns CW Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004 108 130 5 14618627
  72. [80]August DA Landau J Caputo D Ingestion of green tea rapidly decreases prostaglandin E2 levels in rectal mucosa in humans. Cancer Epidemiol Biomarkers Prev 1999 8 709 13 10744131
  73. [81]Wang LD Zhou Q Feng CW Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho 2002 29 159 72 11890101
  74. [82]Jatoi A Ellison N Burch PA A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003 97 1442 6 12627508
  75. [83]Choan E Segal R Jonker D A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005 23 108 13 15869995
  76. [84]Laurie SA Miller VA Grant SC Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 2005 55 33 8 15309507
  77. [85]Shanafelt TD Lee YK Call TG Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006 30 707 12 16325256
  78. [86]Annabi B Lee YT Martel C Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (−) epigallocatechin-3-gallate. Cancer Biol Ther 2003 2 642 9 14688468
  79. [87]Siddiqui IA Malik A Adhami VM Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008 27 2055 63 17998943
  80. [88]Chan MM Soprano KJ Weinstein K Fong D Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 2006 207 389 96 16402374
  81. [89]Golden EB Lam PY Kardosh A Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009 [In Press]; available online: doi:10.1182/blood-2008-07-171389 19190249 · DOI
  82. [90]Sarkar FH Li Y Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002 21 265 80 12549765
  83. [91]Kazi A Daniel KG Smith DM Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003 66 965 76 12963483
  84. [92]Watanabe S Yamaguchi M Sobue T Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998 128 1710 5 9772140
  85. [93]Uehar M Arai Y Watanabe S Adlercreutz H Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 2000 12 217 25 11216489
  86. [94]Sarkar FH Adsule S Padhye S The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 2006 6 401 7 16613577
  87. [95]Kuiper GG Lemmen JG Carlsson B Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998 139 4252 63 9751507
  88. [96]Banerjee S Li Y Wang Z Sarkar FH Multi-targeted therapy of cancer by genistein. Cancer Lett 2008 269 226 42 18492603 PMC2575691
  89. [97]Lampe JW Nishino Y Ray RM Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2007 16 2579 86 18086761
  90. [98]Busby MG Jeffcoat AR Bloedon LT Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002 75 126 36 11756070
  91. [99]Pop EA Fischer LM Coan AD Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a Phase I clinical trial. Menopause 2008 15 684 92 18446090 PMC2574732
  92. [100]Fischer L Mahoney C Jeffcoat AR Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004 48 160 70 15231450
  93. [101]Miltyk W Craciunescu CN Fischer L Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003 77 875 82 12663286
  94. [102]Venkitaraman R Thomas K Grace P Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. Int J Biol Markers 2008 23 192 7 18949747
  95. [103]Kumar NB Krischer JP Allen K A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007 59 163 8 18001210 PMC2435485
  96. Pendleton JM Tan WW Anai S Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008 8 132 Dietary intervention with isoflavone supplementation in a fraction of recurrent prostate cancer patients. 18471323 PMC2394534
  97. [105]Vaishampayan U Hussain M Banerjee M Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007 59 1 7 17927495
  98. [106]Hermann RM Fest J Christiansen H Radiosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro. Strahlenther Onkol 2007 183 195 202 17406801
  99. [107]Honda N Yagi K Ding GR Miyakoshi J Radiosensitization by overexpression of the nonphosphorylation form of IkappaB-alpha in human glioma cells. J Radiat Res 2002 43 283 92 12518988
  100. [108]Raffoul JJ Banerjee S Singh-Gupta V Down-regulation of apurinic/ apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007 67 2141 9 17332344
  101. [109]Schroder FH Roobol MJ Boeve ER Randomized, double-blind, placebo controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005 48 922 30 16263208
  102. [110]Kunnumakkara AB Anand P Aggarwal BB Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008 269 199 225 18479807
  103. [111]von Metzler I Krebbel H Kuckelkorn U Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J Cancer Res Clin Oncol 2009 135 173 9 18766375 PMC12160298
  104. [112]Milacic V Banerjee S Landis-Piwowar KR Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008 68 7283 92 18794115 PMC2556983
  105. [113]Garcea G Jones DJ Singh R Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004 90 1011 5 14997198 PMC2409622
  106. [114]Dhillon N Aggarwal BB Newman RA Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008 14 4491 9 18628464
  107. [115]Cheng AL Hsu CH Lin JK Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001 21 2895 900 11712783
  108. [116]Plummer SM Hill KA Festing MF Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 2001 10 1295 9 11751448
  109. Sharma RA McLelland HR Hill KA Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001 7 1894 900 Effectiveness of oral administration of curcumin-containing extract against colon cancer. 11448902
  110. [118]Sharma RA Euden SA Platton SL Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004 10 6847 54 15501961
  111. [119]Garcea G Berry DP Jones DJ Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005 14 120 5 15668484
  112. [120]Li M Zhang Z Hill DL Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007 67 1988 96 17332326
  113. [121]Javvadi P Segan AT Tuttle SW Koumenis C The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 2008 73 1491 501 18252805 PMC3400533
  114. [122]Chendil D Ranga RS Meigooni D Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004 23 1599 607 14985701
  115. [123]Khafif A Hurst R Kyker K Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 2005 132 317 21 15692547
  116. [124]Yang H Zhou P Huang H Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 2009 124 2450 9 19165859 PMC2707765
  117. [125]Guo XP Zhang XY Zhang SD Clinical trial on the effects of shikonin mixture on later stage lung cancer. Zhong Xi Yi Jie He Za Zhi 1991 11 598 9, 80 1806305
  118. [126]Brar SS Grigg C Wilson KS Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 2004 3 1049 60 15367699
  119. [127]Marikovsky M Nevo N Vadai E Harris-Cerruti C Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 2002 97 34 41 11774241
  120. [128]Cen D Brayton D Shahandeh B Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004 47 6914 20 15615540
  121. [129]Chen D Cui QC Yang H Dou QP Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006 66 10425 33 17079463
  122. [130]Meng L Mohan R Kwok BH Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999 96 10403 8 10468620 PMC17900
  123. [131]Tsukamoto S Yokosawa H Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 2006 13 745 54 16611064
  124. [132]Chen D Daniel KG Chen MS Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005 69 1421 32 15857606
  125. [133]Yang H Shi G Dou QP The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from ‘Indian winter cherry’. Mol Pharmacol 2007 71 426 37 17093135
  126. [134]Yang H Chen D Cui QC Celastrol, a triterpene extracted from the Chinese ‘Thunder of God Vine,’ is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006 66 4758 65 16651429
  127. [135]Ferry DR Smith A Malkhandi J Phase I clinical trial of the flavonoid quercetin:pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996 2 659 68 9816216

Cited by

Sorted by citations

Authors
Yang, H., Zonder, J. A., & Dou, Q. P.
Affiliations
Wayne State University (US)
ORCID
Venue
Expert Opinion on Investigational Drugs
Publisher
Informa UK Limited
Published
2009-06-08
Volume
18
Issue
7
Pages
957-971
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
DOI
10.1517/13543780903002074
PMC
PMC3758888
OpenAlex
W2036211695
Cited by
85
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 14 · 2013: 6 · 2012: 7
FWCI
0.89
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R03CA112625, R01CA120009, P30CA022453)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
proteasome inhibitors, bortezomib, carfilzomib, NPI-0052, multiple myeloma, hematologic malignancies, solid tumors, natural products, epigallocatechin gallate, genistein, curcumin, chemoprevention, combination therapy, clinical trials
MeSH terms
Animals, Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, Treatment Outcome, Proteasome Endopeptidase Complex, Drug Discovery, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review